IQVIA Holdings Inc.

NYSE:IQV

Medical - Diagnostics & Research

Healthcare
$257.84 -1.83%

-$3.13 today

Market cap
$42.49B
Beta
1.22
P/E (TTM)
20.4
EPS (TTM)
$8.22
52W Low $153.01High $247.05

Volume 1.40M

Average 1.62M

IQV EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

IQVIA Holdings Inc.NYSE: IQV

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows, but more slowly than its trailing trend

Q2 FY2026 EBITDA of $790M rose 1.2% year over year, behind the +5.3% change in trailing-twelve-month EBITDA. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at +0.3% a year.

Context

  • EBITDA amounted to 18.0% of revenue in FY2025, down 4.4 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 14 analysts of $3.99B (+36.0%) for the fiscal year ending Dec 2026, a step up from the -14.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$790M-2.2% QoQ
Last fiscal yearDec 2025
$2.94B-14.9% YoY
LTMJun 2026
$3.53B+5.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.2%+31.8%+30.6 pp
1 year-14.9%+36.0%+50.9 pp
3-year CAGR+0.3%+15.5%+15.1 pp
5-year CAGR+13.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
2.94B USD
Year-over-year change
-14.9%
4-year CAGR
+1.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How IQV compares with its peers on the latest reported figures

  • IQV's LTM Jun 2026 EBITDA of $3.53B is the highest of the 9 companies compared; the peer median is $160.87M.
  • Its year-over-year change of +5.3% is the 5th highest of 9, against a peer median of +4.1%.
  • EBITDA amounts to 20.8% of revenue for IQV, versus a peer median of 18.9%.
IQV Competitors Peer median
EBITDA for IQV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IQVIQVIA Holdings Inc.LTM Jun 2026$3.53B +5.3%+0.3%20.8%
VEEVVeeva Systems Inc.LTM Jul 2026$1.37B +25.9%+32.3%39.7%
ICLRICON Public Limited CompanyLTM Jun 2026$1.25B -9.3%-15.5%15.1%
MEDPMedpace Holdings, Inc.LTM Sep 2026$643.55M +17.5%+22.8%22.7%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$220.47M -58.3%-25.3%5.5%
CERTCertara, Inc.LTM Mar 2026$101.27M +78.1%-1.9%24.1%
FTREFortrea Holdings Inc.LTM Jun 2026$81.2M +109.5%—3.0%
TEMTempus AI, Inc.LTM Sep 2026-$108.97M -19.4%—7.2%
HCATHealth Catalyst, Inc.LTM Mar 2026-$192.37M -1267.9%—63.6%
Peer median (excluding IQV) $160.87M+4.1%-1.9%18.9%

Competitors are the stored peer set for IQV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.87B14.41B14.98B15.41B16.31B
Cost of Revenue9.23B9.38B9.75B10.03B10.88B
Gross Profit4.64B5.03B5.24B5.38B5.43B
Gross Margin33.5%34.9%35.0%34.9%33.3%
Research & Development00000
Selling, General & Admin1.96B2.07B2.05B1.99B1.99B
Operating Expenses3.25B3.23B3.26B3.17B3.25B
Depreciation & Amortization1.26B1.13B1.13B1.11B640M
EBITDA2.77B2.91B3.26B3.45B2.94B
EBITDA Margin19.9%20.2%21.7%22.4%18.0%
Operating Income1.39B1.8B1.98B2.2B2.18B
Operating Margin10.0%12.5%13.2%14.3%13.4%
Interest Income6M13M36M47M45M
Interest Expense375M416M672M670M729M
Other Income / Expenses(259M)(448M)(518M)(533M)(569M)
Income Before Tax1.13B1.35B1.46B1.67B1.61B
Pre-Tax Margin8.2%9.4%9.7%10.8%9.9%
Income Tax Expense163M260M101M296M252M
Net Income966M1.09B1.36B1.37B1.36B
Net Margin7.0%7.6%9.1%8.9%8.3%
EPS (Basic)5.055.827.397.577.91
EPS (Diluted)4.955.727.297.497.84
Weighted Avg Shares191.4M187.6M183.8M181.3M171.9M
Weighted Avg Shares (Diluted)195M190.6M186.3M183.4M173.5M

IQVIA Holdings Inc.

NYSE:IQV

Intrinsic Alpha fair value

Locked

Current Price

$257.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.